Lack of safety data in lactation: The primary concern is the absence of controlled studies examining CoQ10 supplementation during breastfeeding
doi: 10.1093/ije/18.1.45 80 JonklaasJDanielsenMWangH
DeFronzo said a glucagon-like peptide 1 receptor agonist (GLP-1 RA) will correct six of the disturbances present in Type 2 diabetes individuals, sodium-glucose co-transporter 2 (SGLT2) inhibitor treatment corrects three of the metabolic abnormalities, and pioglitazone fixes four of the problems with some overlap with the GLP-1 RAs and SGLT2i
[DOI] [PubMed] [Google Scholar] 50.Kang E.A., Han Y.M., An J.M., Park Y.J., Sikiric P., Kim D.H., Kwon K.A., Kim Y.J., Yang D., Tchah H., et al
Triple Agonists (GLP-1 + GIP + Glucagon): Retatrutide, developed by Eli Lilly, takes the logic a step further by adding a glucagon receptor target
Caractersticas Principales